High-dose anticoagulation can reduce intubations and improve survival for hospitalized COVID-19 patients

High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation. These are the significant findings from the large-scale international “FREEDOM” trial, led by Valentin Fuster, MD, Ph.D., President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of the Spanish National Center for Cardiovascular Research (CNIC).

Researchers discover link between PSA level at time of salvage therapy following surgery and risk of death

The performance characteristics of prostate-specific membrane antigen positron emission tomography improves with increasing prostate-specific antigen (PSA) level. This, coupled with insurance approval concerns if applied for too early, causes some physicians to delay post-radical prostatectomy salvage radiation therapy (sRT) until well after PSA failure, typically at PSA levels exceeding 0.30 ng/ml.

Sharp rise in cardiovascular risk factors among young adults may foreshadow public health crisis

In the United States, one person dies every 34 seconds from cardiovascular disease, making it the leading cause of death for men, women, and people of most racial and ethnic groups. While medical advances prompted steady declines in cardiovascular mortality throughout the second half of the 20th century, that progress has stalled over the past decade.